-
1.发明申请公开(公告)号：US20190169217A1
公开(公告)日：2019-06-06
申请号：US16031889
申请日：2018-07-10
IPC分类号： C07H13/12 , C07D487/08 , C07H15/18 , C07D401/12 , C07D337/08 , C07D285/36 , C07D211/08 , C07D207/04 , A61K45/06 , A61K31/7042 , A61K31/554 , A61K31/5377 , A61K31/4995 , A61K31/495 , A61K31/454 , A61K31/4453 , A61K31/4436 , A61K31/40 , A61K31/38 , A61K31/155 , C07H15/26 , C07C257/10 , C07D413/12 , C07D281/10 , C07D295/13 , A61K31/7028 , C07C279/12 , C07D211/06
摘要： Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
-
2.发明申请公开(公告)号：US20200207797A1
公开(公告)日：2020-07-02
申请号：US16696196
申请日：2019-11-26
IPC分类号： C07H13/12 , C07D295/13 , C07D281/10 , C07D211/06 , C07C279/12 , A61K31/7028 , C07H15/26 , C07D487/08 , C07D413/12 , C07D401/12 , C07D337/08 , C07D285/36 , C07D211/08 , C07D207/04 , C07C257/10 , A61K45/06 , A61K31/7042 , A61K31/554 , A61K31/5377 , A61K31/4995 , A61K31/495 , A61K31/454 , A61K31/4453 , A61K31/4436 , A61K31/40 , A61K31/38 , A61K31/155 , C07H15/18
摘要： Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20200246366A1
公开(公告)日：2020-08-06
申请号：US16679864
申请日：2019-11-11
IPC分类号： A61K31/7042 , A61K31/41 , A61K31/495 , A61K31/4965 , A61K31/4985 , A61K31/5377 , A61K31/155 , A61K31/38 , A61K31/554 , A61K31/4436 , A61K31/4995 , A61K45/06 , C07D281/10 , C07D337/08 , C07D409/10 , C07D487/08 , C07H15/26 , A61K9/00 , A61K9/16 , A61K9/20
摘要： Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
-
-
搜索结果
3 条记录 (耗时 0.015 秒)
